RE:RE:RE:RE:RE:RE:RE:RE:Bullboard...TLT is much more advanced than Briacell as we are already 40% into a Ph. 2b, with superior results than competition and an confirmation that TLD-1433 detroys cancer cells. We just need a bit more data to make a trend more significant, see how many PR and pending convert to CR and how our DR (@450-days) trends. The 270-days data is also important to monitor for the fully dosed patients.
We are also closer to a Breakthrough designation.
Moreover, Roger owns 7.5M shares. So I doubt a reverse split would be to his advantage before any Breakthrough designation and a Breakthrough designation would take care of the market valuation by itself when taking the example of ...
COVID-19 has slowed our Ph. 2b trial on at least 3 occasions. We would be much more advanced in our number of patient enrolled and treated. On the other side, COVID-19 created an opportunity to enter into the anti-virus indication and so far so good, but still in preclinical, so not bringing any valuation for the moment.